Actimab-A: Additional Phase I/II data

Data from 14 previously untreated AML patients ages >=60 in the Phase I portion of an open-label, U.S. Phase I/II trial showed that 0.5, 1, 1.5 and 2 uCi/kg/fraction doses of Actimab-A plus low-dose c...